Mild hepatitis C infection will rapidly worsen in one in three people affectedFebruary 11, 2004Mild hepatitis C infection will rapidly worsen in one in three of those affected, suggests research in Gut. This is particularly likely in those who are older when first infected, and those who already have a degree of inflammation and scar tissue (fibrosis) in their liver at diagnosis. The viral liver infection hepatitis C (HCV) is mainly passed on through injecting drug use and blood transfusions before 1991, when the screening of blood products for the virus was introduced. HCV is an important cause of chronic liver disease, eventually leading to liver cancer. But treatment with interferon is complicated and expensive, and only works in around one in two of those treated. The authors base their conclusions on 214 patients with HCV whose average age was 36; 126 of them were men and their liver disease was mostly mild. None of the patients was given any treatment, and they were monitored by tissue sampling of their liver (biopsy) every 2.5 years. One in two of the patients admitted to having used intravenous drugs in the past; almost one in four had been transfused with infected blood products. At the first biopsy, the average fibrosis score (Ishak score) was 3. Most patients had scores of 6 or less; scores of up to 6 are considered to denote mild disease. Within 30 months, when the next tissue sample was taken, the Ishak score had increased by one or more points in a third (70) of the patients, and by two or more points in one in 10 of them. The factors influencing progression of the disease were older age at infection, rather than the length of infection, and degree of inflammation and scarring at the first biopsy. Unlike the results of previous research, gender, alcohol consumption, virus type and other indicators of poor liver function did not seem to have any effect on the rate of progression, although the authors point out that it is important to reduce alcohol consumption once infected. The authors conclude that even mild HCV is a progressive disease, and those patients affected are likely to require a considerable degree of health care as they age over the next 20 years. | |||||||||||||||||||||
|
Related Hepatitis Current Events and Hepatitis News Articles Childhood vaccines cause financial burden to many health care providers The costs that health care providers are charged and reimbursed for childhood vaccines vary widely, and the high cost of some immunizations is leading to significant financial strain for some physicians, according to a pair of new studies from the University of Michigan Health System. Antibiotics: Single largest class of drugs causing liver injury Antibiotics are the single largest class of agents that cause idiosyncratic drug-induced liver injury (DILI), reports a new study in Gastroenterology, an official journal of the American Gastroenterological Association (AGA) Institute. Study unmasks how ovarian tumors evade immune system Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. Common cold virus came from birds A virus that causes cold-like symptoms in humans originated in birds and may have crossed the species barrier around 200 years ago, according to an article published in the December issue of the Journal of General Virology. Scientists hope their findings will help us understand how potentially deadly viruses emerge in humans. Study finds Canada's supervised injection facility cost-effective Canada's only supervised injection facility is extending lives and saving the health-care system millions of dollars, a new study shows. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time. Pakistan introduces vaccine to prevent top child killer This month, Pakistan is introducing a new combination vaccine that will protect its children against the bacterium Haemophilus influenzae type b (Hib) and four other common childhood diseases. More Hepatitis Current Events and Hepatitis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||